Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2015	Feb. 29, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 27.0
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		11,833,801

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 2,485	$ 774
Marketable securities (Note 4)	10,837	11,322
Accounts receivable, net of allowances of $91 and $5	83	76
Accrued investment income	37	66
Inventories, net (Note 5)	276	304
Prepaid expenses and other current assets	417	471
Other current deferred assets	0	218
Total current assets	14,135	13,231
Property, plant and equipment, net (Note 6)	1,013	957
Intangible asset, net of accumulated amortization of $362 and $155 (Note 3)	1,638	1,845
Other assets	175	0
Total assets	16,961	16,033
Current liabilities:
Accounts payable	110	217
Accrued expenses (Note 7)	564	568
Accrued interest	0	70
Other current liabilities	45	26
Sales returns liability	205	0
Deferred revenue	0	353
Current maturities of long-term debt (Note 8)	2,320	1,758
Total current liabilities	3,244	2,992
Long-term debt, net of debt discount of $193 and $281 and debt issuance costs of $97 and $162 (Note 8)	5,430	7,799
Long-term portion of accrued interest	387	190
Total liabilities	$ 9,061	$ 10,981
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 11,801 and 9,770 shares issued and outstanding at 2015 and 2014, respectively	$ 118	$ 98
Additional paid-in capital	375,157	367,288
Accumulated deficit	(367,310)	(362,321)
Accumulated other comprehensive loss	(65)	(13)
Total stockholders' equity	7,900	5,052
Total liabilities and stockholders' equity	$ 16,961	$ 16,033

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts receivable, net of allowances	$ 91	$ 5
Finite-lived intangible assets accumulated amortization	362	155
Long-term debt, net of debt discount	193	281
Debt Instrument Issuance Cost	$ 97	$ 162
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	11,801	9,770
Common stock, shares outstanding	11,801	9,770

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues:
License fee revenue	$ 5,250	$ 500
Milestone revenue	2,500	0
Collaboration revenue	170	0
Royalty revenue	5	4
Product sales, net	662	247
Total revenues, net	8,587	751
Operating expenses:
Cost of sales (excluding inventory write-down)	656	227
Inventory write-down (Note 5)	330	201
Research and development	2,608	4,582
Selling, marketing, general and administrative	8,994	7,940
Total operating expenses	12,588	12,950
Operating loss	(4,001)	(12,199)
Non-Operating income (expense):
Investment income	166	198
Interest expense (Note 8)	(1,157)	(1,212)
Other income	3	4
Total other expense, net	(988)	(1,010)
Loss before income taxes	(4,989)	(13,209)
Provision for income taxes	0	0
Net loss	(4,989)	(13,209)
Other comprehensive loss:
Unrealized losses on marketable securities	(52)	(32)
Total other comprehensive loss	(52)	(32)
Comprehensive loss	$ (5,041)	$ (13,241)
Loss per share:
Basic	$ (0.46)	$ (1.35)
Diluted	$ (0.46)	$ (1.35)
Weighted average shares outstanding:
Basic	10,796	9,779
Diluted	10,796	9,779

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Restricted Stock Units (RSUs)	Cashless	Common Stock	Common Stock Restricted Stock Units (RSUs)	Common Stock Cashless	Additional paid-in capital	Additional paid-in capital Restricted Stock Units (RSUs)	Additional paid-in capital Cashless	Accumulated deficit	Accumulated deficit Restricted Stock Units (RSUs)	Accumulated deficit Cashless	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Restricted Stock Units (RSUs)	Accumulated Other Comprehensive Income (Loss) Cashless
Balance at Dec. 31, 2013	$ 17,923			$ 97			$ 366,919			$ (349,112)			$ 19
Balance (in shares) at Dec. 31, 2013				9,665
Net loss	(13,209)			$ 0			0			(13,209)			0
Other comprehensive loss	(32)			0			0			0			(32)
Share-based compensation	890			0			890			0			0
Net distribution of common stock pursuant to restricted stock unit award plan	1			$ 2			(1)			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				165
Common shares withheld for withholding taxes		$ (525)	$ (4)		$ (1)	$ 0		$ (524)	$ (4)		$ 0	$ 0		$ 0	$ 0
Common shares withheld for withholding taxes (in shares)					(63)	0
Issuance of common stock	0			$ 0			0			0			0
Issuance of common stock (in shares)				2
Issuance of common stock for exercise of stock options	8			$ 0			8			0			0
Issuance of common stock for exercise of stock options (in shares)				1
Balance at Dec. 31, 2014	5,052			$ 98			367,288			(362,321)			(13)
Balance (in shares) at Dec. 31, 2014				9,770
Net loss	(4,989)			$ 0			0			(4,989)			0
Other comprehensive loss	(52)			0			0			0			(52)
Share-based compensation	606			0			606			0			0
Net distribution of common stock pursuant to restricted stock unit award plan	0			$ 0			0			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				19
Modification to warrants issued with promissory notes	33			$ 0			33			0			0
Issuance of common stock	7,033			$ 20			7,013			0			0
Issuance of common stock (in shares)				1,958
Issuance of common stock under “at the market” offerings, net of offering costs of $8	217			$ 0			217			0			0
Issuance of common stock under “at the market” offerings, net of offering costs of $8 (in shares)				54
Balance at Dec. 31, 2015	$ 7,900			$ 118			$ 375,157			$ (367,310)			$ (65)
Balance (in shares) at Dec. 31, 2015				11,801

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities:
Net loss	$ (4,989)	$ (13,209)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	125	119
Provision to reduce inventory to net realizable value	330	201
Provision for sales returns	267	0
Share-based compensation	606	890
Amortization of debt discount and debt issuance costs	186	188
Amortization of bond premium in marketable securities	127	250
Amortization of intangible asset	207	155
Gain on sales of marketable securities	(3)	(4)
Loss on disposals of property, plant and equipment	19	0
Changes in assets and liabilities:
Accounts receivable, net	(69)	118
Accrued investment income	29	54
Inventories	(302)	(254)
Prepaid expenses and other current assets	54	158
Other current deferred assets	218	(32)
Other assets	(175)	5
Accounts payable	(107)	(57)
Accrued expenses	(4)	27
Deferred revenue	(353)	66
Accrued interest - current and long term	127	260
Other current and non-current liabilities	19	21
Net cash used in operating activities	(3,688)	(11,044)
Cash Flows from Investing Activities:
Purchases of marketable securities	(3,522)	(2,203)
Proceeds from sale and maturities of marketable securities	3,830	4,336
Acquisition of product rights	0	(2,000)
Additions to property, plant and equipment	(214)	(135)
Proceeds from disposal of property and equipment	14	0
Net cash provided by (used in) by investing activities	108	(2)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	8
Proceeds from distribution of restricted stock units	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	0	(529)
Proceeds from “at-the-market” offering	225	0
Proceeds from registered direct offering	7,636	0
Offering transaction costs	(611)	0
Principal payments on debt	(1,960)	0
Net cash provided by (used in) financing activities	5,291	(520)
Net increase (decrease) in cash and cash equivalents	1,711	(11,566)
Cash and cash equivalents at beginning of year	774	12,340
Cash and cash equivalents at end of period	2,485	774
Cash paid (refunded) during the year for:
Interest	844	765
Income taxes, net of refunds	$ 0	$ 14

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($) shares
Stock options
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted	5
Common stock withheld in exercise costs in shares	3
Common stock withheld in exercise costs \| $	$ 32
Withholding of exercise cost in shares	1
Minimum statutory withholding payroll taxes withheld \| $	$ 4
Common Stock issued upon exercise	1
Restricted Stock Units (RSUs) [Member]
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted	166
Common stock withheld in exercise costs in shares	1
Common stock withheld in exercise costs \| $	$ 7
Withholding of exercise cost in shares	63
Minimum statutory withholding payroll taxes withheld \| $	$ 525
Common Stock issued upon exercise	102

DESCRIPTION OF BUSINESS

12 Months Ended

Dec. 31, 2015

Description Of Business Disclosure [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® and Limitx™ Technologies are intended to address methods of product tampering associated with opioid abuse while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine. Oxaydo® Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first and only approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. We launched our first Impede Technology product, Nexafed, into the United States market in December 2012 and launched our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC (“Bayer”) entered into a License and Development Agreement (the “Bayer Agreement”) pursuant to which we granted Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine – containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. Our third abuse deterrent technology, Limitx, is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. In January 2016, our Investigational New Drug Application, or IND, filed with the FDA for our lead Limitx oral abuse deterrent drug candidate using the opioid hydromorphone HC1 (“LTX-04”), was allowed to proceed to clinical testing. We have commenced our initial Phase I exploratory pharmacokinetic study of LTX-04. We are also developing an immediate-release hydrocodone bitartrate with acetaminophen product utilizing our Limitx technology.

Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data. The equity amounts and all share and per share data of the Company have been retroactively adjusted to reflect a one-for-five reverse stock split effected by us on August 28, 2015.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions.

Reclassifications

Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation.

Management Estimates

Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.

Cash and Cash Equivalents

The Company considers cash and cash equivalents to include cash in financial institutions and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.

Marketable Securities

The Company’s marketable securities at December 31, 2015 and 2014 primarily consist of corporate debt securities and exchange-traded funds. Our marketable securities are governed by our investment policy as approved by our Board of Directors. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices or net asset value. Unrealized temporary adjustments to fair value are included in a separate component of stockholders’ equity as unrealized gains and losses and reported as a component of accumulated other comprehensive income (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.

Fair Value of Other Financial Instruments

The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, trade accounts payable, accrued expenses and our long-term debt. The carrying amounts of these financial instruments, other than marketable securities and our long-term debt, are representative of their respective fair values due to their relatively short maturities. The Company believes the fair value of long-term debt approximates its carrying value based upon the borrowing rates currently available to the Company for loans with similar terms. As discussed above, marketable securities are recorded at fair value.

Concentration of Credit Risk

Credit Risk: Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company’s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities.

Customers: We launched our first Impede Technology product, Nexafed®, in the United States in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. Our accounts receivable arise from our sales of our Nexafed product line and represent amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and may maintain an allowance for potentially uncollectable accounts. We have not experienced any losses on uncollectable accounts in 2015 or 2014.

Sales to certain of our customers during 2015 and 2014 accounting for 10% or more of our annual product sales, whether the product shipment was recognized immediately as a sales or as a deferred sale, are presented below. Sales to customers designated with an “ * ” accounted for less than 10% of our annual product sales.

Customer	2015			2014
Rite Aid Corporation		54	%		28	%
Cardinal Health, Inc.		14	%		24	%
AmerisourceBergen Corporation		*			13	%
McKesson Corporation		*			13	%
Kroger Foods		*			11	%

Accounts receivable from certain of our customers at December 31, 2015 and 2014 accounting for 10% or more of our gross accounts receivable are presented below. Accounts receivable from customers designated with an “ ** ” accounted for less than 10% of our gross accounts receivable.

Customer	2015			2014
Rite Aid Corporation		68	%		83	%
McKesson Corporation		11	%		**
Kroger Foods		**			13	%

Inventories

Inventories at December 31, 2015 consist of finished goods held for distribution and sale on our Nexafed® product line. Inventories at December 31, 2014 consisted of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed® product. During 2014, we purchased raw material and packaging material inventories for $260 thousand from Pfizer on the Oxaydo product we reacquired from them. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.

Our purchases of active pharmaceutical ingredients and raw materials required for our development and clinical trial manufacture of product candidates utilizing our Aversion®, Impede® or Limitx Technologies are expensed as incurred.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts.

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

Deferred Debt Issuance Costs and Debt Discount

Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method. See Recent Accounting Pronouncements for discussion on the presentation of deferred debt issuance costs as a direct reduction against long-term debt.

License Fee Revenue

In December 2014, the Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered on the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering into an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to Acura including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue relating to the December 2014 agreement. These amounts were recognized as revenue when received.

On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) entered into a Collaboration and License Agreement to commercialize Oxaydo tablets (formerly known as Oxecta) utilizing our Aversion® Technology. Egalet paid us $5.0 million upon signing the Egalet Agreement. The payment was non-refundable and non-creditable when made and we had no further requirements to earn the payment. The amount was recognized as revenue when received (see Note 3).

Milestone Revenue

Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made and is recognized as revenue when received. In October 2015, Egalet paid us a $2.5 million milestone payment in connection with the event of the first commercial sale of Oxaydo.

Collaboration Revenue

Collaboration revenue is derived from reimbursement of development expenses, such as under our agreement with Bayer, and are recognized when costs are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreements. We recognized $170 thousand of collaboration revenue during the year 2015.

Royalty Revenue

In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. Egalet’s first commercial sale of Oxaydo occurred in October 2015 and we have recorded royalties of $5 thousand on net sales during the fourth quarter 2015 (see Note 3).

In connection with our License, Development, and Commercialization Agreement dated October 30, 2007 with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer Inc. (the “Pfizer Agreement”), we began earning royalties on Oxecta starting in February 2013. We recorded royalties of approximately $4 thousand for the year ended December 31, 2014. Effective April 9, 2014, the Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer (see Note 3).

Product Sales

Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. The Nexafed products currently have a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers. During 2014, we continued deferring the recognition of revenue and at December 31, 2014 we had accumulated deferred revenue of $353 thousand of Nexafed shipments. During the first quarter of 2015, we determined we had obtained sufficient sales returns history to reasonably estimate future product returns from those customers. We recorded a one-time adjustment in the first quarter of 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $314 thousand after recording a liability for sales returns of $120 thousand, and recorded cost of sales of $255 thousand. We currently recognize revenue from our Nexafed product line when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated, which generally occurs at the time of product shipment. At December 31, 2015, we have a $205 thousand sales returns liability which will be reviewed against sales returns activity each calendar quarter for adjustment.

Advertising Costs

The Company records the cost of its advertising efforts when services are performed or goods are delivered.

Shipping and Handling Costs

The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material.

Impairment of Long-Lived Assets

Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We had no impairment charges for the years ended 2015 and 2014.

Research and Development Activities

Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. During 2015, we entered into a cancelable arrangement for contract manufacturing services on a project to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. Approximately $0.2 million was remaining under this agreement at December 31, 2015. During 2014, we entered into several cancelable CRO arrangements and our remaining obligations under these arrangements were approximately $0.1 million at December 31, 2014 for services to be incurred as subjects are enrolled and progress through the studies. We did not have prepaid CRO costs and clinical trial study expenses at either December 31, 2015 or 2014.

Share-based Compensation

We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands):

	Year ended December 31,
	2015		2014
Research and development:
Stock option awards	$	158	$	220
RSU awards		-		-
	$	158	$	220

Selling, general and administrative:
Stock option awards		384		550
RSU awards		95		146
	$	479	$	696

Total share-based compensation expense	$	637	$	916

Comprehensive Income (Loss)

Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that, under GAAP, are included in comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income (loss) is composed of unrealized gains (losses) on certain holdings of marketable securities, net of any realized gains (losses) included in net income (loss).

Income Taxes

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At December 31, 2015 and 2014, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

Earnings Per Share (“EPS”)

Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 11). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2015 or 2014 as the Company reported a net loss for the years and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands, except per share data):

	Years ended December 31,
	2015		2014
EPS – basic
Numerator: net loss	$	(4,989)	$	(13,209)
Denominator (weighted):
Common shares		10,777		9,770
Vested RSUs		19		9
Basic weighted average shares outstanding		10,796		9,779
EPS - basic	$	(0.46)	$	(1.35)

EPS – assuming dilution
Numerator: net loss	$	(4,989)	$	(13,209)
Denominator (weighted):
Common shares		10,777		9,770
Vested RSUs		19		9
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		10,796		9,779
EPS - diluted	$	(0.46)	$	(1.35)

Excluded dilutive securities:
Common stock issuable (non weighted):
Stock options		1,198		911
Common stock warrants		60		60
Total excluded potentially dilutive shares		1,258		971

Recent Accounting Pronouncements

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the transition method we will utilize to adopt the standard for use in 2018.

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, which will explicitly require management to assess an entity’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Currently, there is no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for the first annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of adopting this update on its financial statements.

Presentation of Debt Issuance Costs

In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. Early adoption of the amendments is permitted and the Company elected to adopt this guidance effective April 1, 2015. The Company adopted the guidance to implement the simplified presentation prescribed as the purpose of the amendment. The new guidance has been applied on a retrospective basis, wherein the consolidated balance sheets of December 31, 2014 have been retrospectively adjusted to reflect the effects of applying the new guidance. As a result of the change to the December 31, 2014 consolidated balance sheet, deferred debt issuance costs and long-term debt decreased and increased, respectively, by $162 thousand. After the retrospective application to December 31, 2014, subsequent amortization of the deferred debt issuance costs results in an increase to long-term debt.

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

12 Months Ended

Dec. 31, 2015

Research and Development Disclosure [Abstract]

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT

NOTE 3 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

Egalet Agreement

On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us a $5.0 million license fee upon signing of the Egalet Agreement and a $2.5 million milestone on October 9, 2015 in connection with the first commercial sale of Oxaydo. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

Bayer Agreement

On June 15, 2015, we and Bayer entered into a License and Development Agreement (the “Bayer Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine –containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Agreement also grants Bayer first right to negotiate a license to the Impede technology for certain other products.

We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We will be eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed Product in countries with patent coverage and a reduced royalty elsewhere.

The term of the Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Agreement in its entirety if the other party materially breaches the Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time.

Terminated Pfizer Agreement

In 2007, we entered into License, Development and Commercialization Agreement for Oxaydo (named Oxecta™ under a Pfizer trademark) and other Aversion opioid development products with King Pharmaceuticals Research and Development, Inc., which became a subsidiary of Pfizer in 2011 (the “Pfizer Agreement”). In April 2014, we entered into two letter agreements with Pfizer providing for the termination of the Pfizer Agreement and the return to us of Oxaydo and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our consolidated financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Oxaydo. During the year ended December 31, 2015 and 2014, we recorded amortization expense of $207 thousand and $155 thousand, respectively. We also purchased from Pfizer selected raw and packaging material inventories for $260 thousand relating to Oxaydo. In 2015, we wrote off and disposed of these inventories.

INVESTMENTS IN MARKETABLE SECURITIES

12 Months Ended

Dec. 31, 2015

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS IN MARKETABLE SECURITIES

NOTE 4 – INVESTMENTS IN MARKETABLE SECURITIES

Investments in marketable securities consisted of the following (in millions):

	December 31, 2015		December 31, 2014
Marketable securities:
Corporate bonds — maturing within 1 year	$	3.1	$	3.5
Corporate bonds — maturing after 1 year and through March 2017		0.4		2.8
Exchange-traded funds		7.3		5.0
Total marketable securities	$	10.8	$	11.3

The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our marketable securities are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs.

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	December 31, 2015
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	3.6	$	-	$	(0.1)	$	3.5
Exchange-traded funds		7.3		-		-		7.3
Total - Current	$	10.9	$	-	$	(0.1)	$	10.8

	December 31, 2014
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted market prices in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable market-based inputs or unobservable inputs that are corroborated by market data. Fair values determined based on Level 3 inputs utilize unobservable inputs reflecting the reporting entity’s own assumptions. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Our assets measured at fair value or disclosed at fair value on a recurring basis as at December 31, 2015 and 2014 consisted of the following (in millions):

	December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		3.5		-		3.5		-
Exchange-traded funds		7.3		7.3		-		-
Total	$	10.8	$	7.3	$	3.5	$	-

	December 31, 2014
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		6.3		-		6.3		-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3	$	5.0	$	6.3	$	-

Accumulated Other Comprehensive Income (Loss)

Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at December 31, 2015 and 2014 consisted of unrealized losses on securities of $65 thousand and $13 thousand, respectively.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

INVENTORIES

12 Months Ended

Dec. 31, 2015

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 5 – INVENTORIES

Inventories at December 31, 2015 consist of finished goods held for distribution and sale on our Nexafed product line. Inventories at December 31, 2014 consisted of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on Nexafed product. During 2014, we purchased selected raw and packaging material inventories for $260 thousand from Pfizer related to the Oxaydo product we reacquired from them (see Note 3). During 2015, we wrote off and disposed of the inventories. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.

At December 31, 2014 we had deferred revenue of $350 thousand from our Nexafed product shipments to customers. The related cost of sales of $218 thousand is reported in our balance sheet in the other current deferred assets account and excluded from the reported year end inventories at December 31, 2014. During 2015, we recorded a one-time adjustment to recognize revenue that had previously been deferred, resulting in additional net revenues of $314 thousand after recording a liability for sales returns of $120 thousand, and we recorded cost of sales of $255 thousand.

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories are summarized as follows (in thousands):

	December 31,
	2015		2014
Raw and packaging	$	-	$	260
Finished goods		346		44
Total inventory		346		304
Less: inventory reserve - finished goods		(70)		(-)
Net inventory	$	276	$	304

Inventory reserve activity during the years ended December 31, 2015 and 2014 was as follows (in thousands):

	2015		2014
Beginning of year	$	-	$	250
Reserve expense - raw and packaging		260		-
Reserve expense - finished goods		70		201
		330		451
Inventory write-offs - raw and packaging		(260)		-
Inventory write-offs - finished goods		-		(451)
End of year	$	70	$	-

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are summarized as follows (in thousands):

	December 31,
	2015		2014
Building and improvements	$	1,265	$	1,259
Scientific equipment		598		595
Computer hardware and software		124		252
Machinery and equipment		508		386
Land and improvements		162		162
Other personal property		70		70
Office equipment		27		27
		2,754		2,751
Less: accumulated depreciation		(1,741)		(1,794)
Total property, plant and equipment, net	$	1,013	$	957

Depreciation expense was approximately $0.1 million for each of the years ended December 31, 2015 and 2014.

DEBT

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

DEBT

NOTE 8 – DEBT

On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The full principal amount of the Term Loan was funded on December 27, 2013. We are using the proceeds of the Loan Agreement for general working capital and to fund our business requirements. The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest-only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As of December 31, 2015, we have made $1.96 million in principal payments. As security for its obligations under the Loan Agreement, the Company granted Lender a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020. The fair value of the warrants was determined using the Black-Scholes option-pricing model. Significant assumptions used in the Black-Scholes model were:

Expected dividend yield	0.0	%
Risk-free interest rate	2.4	%
Expected volatility	92	%
Expected term (years)	7

On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the Warrants was lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the warrant modification, (ii) we agreed to maintain $2.5 million cash reserves until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.

The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 1% of the principal prepaid. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We are accruing additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of 10.16%.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt is summarized below (in thousands):

Long-term Debt	Current		Long-term		Total
Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
Principal payments		(1,960)		-		(1,960)
Classification		2,522		(2,522)		-
Balance at Dec 31, 2015	$	2,320	$	5,720	$	8,040

Debt Discount	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(281)	$	(281)
Modification of warrants		-		(33)		(33)
Amortization expense		-		121		121
Balance at Dec 31, 2015	$	-	$	(193)	$	(193)

Deferred Debt Issuance Costs	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(162)	$	(162)
Amortization expense		-		65		65
Balance at Dec 31, 2015	$	-	$	(97)	$	(97)

Long-term Debt, net at Dec 31, 2015	$	2,320	$	5,430	$	7,750

Our interest expense consisted of the following (in thousands):

	2015		2014
Interest expense:
Term Loan	$	971	$	1,024
Debt discount		121		119
Debt issue costs		65		69
Total interest expense	$	1,157	$	1,212

The annual principal payments of the debt at December 31, 2015 are as follows:

	Annual Principal Payments
Year	(in thousands)
2016	$	2,320
2017		2,741
2018		2,979
Total	$	8,040

EQUITY FINANCINGS

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

EQUITY FINANCING

NOTE 9 – EQUITY FINANCINGS

Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we could sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $13 million. We did not sell any shares of our common stock pursuant to our prospectus supplement during the year ended December 31, 2014. During the year ended December 31, 2015, we sold approximately 54 thousand shares of our common stock (after giving effect to our one-for-five reverse stock split) for gross proceeds of $225 thousand. Transaction costs were approximately $8 thousand. The net proceeds of $217 thousand were used for general corporate purposes. In order to allow for the sale of our shares of common stock under our shelf registration statement pursuant to the Placement Agency Agreement and Securities Purchase Agreement described below, on June 30, 2015, we and MLV & Co., LLC, as sales agent, terminated the at-market issuance sales agreement dated April 18, 2013, thereby terminating any further “at the market offerings” under our prospectus supplement filed with the SEC on April 18, 2013.

On June 30, 2015, we entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), pursuant to which we engaged Roth to act as sole placement agent in a registered direct offering (the “Offering”) of 1.958 million shares of our common stock, par value $.01 (after giving effect to our one-for-five reverse stock split). On June 30, 2015, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which we agreed to sell 1.958 million shares of our common stock at a price of $3.90 per share (after giving effect to our one-for-five reverse stock split) to the Purchasers in the Offering, for gross proceeds to the Company of $7.64 million, before expenses. The Offering was made pursuant to a prospectus supplement dated June 30, 2015 filed with the Securities and Exchange Commission in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-187075), which became effective on March 15, 2013, and the related base prospectus included in the Registration Statement, as supplemented by the prospectus supplement. The transactions contemplated by the Placement Agency Agreement and the Purchase Agreement closed on July 7, 2015.

Pursuant to the terms of the Placement Agency Agreement, we paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering or $496 thousand, and reimbursed Roth $35 thousand for its expenses. The net proceeds from the Offering, after these and other legal expenses, was $7.0 million.

COMMON STOCK WARRANTS

12 Months Ended

Dec. 31, 2015

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

NOTE 10 – COMMON STOCK WARRANTS

We have outstanding common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. See Note 8 for a discussion of the reduction of the exercise price of these warrants to $2.52 per share which were originally issued in connection with the issuance of the $10.0 million secured promissory notes in December 2013. These warrants contain a cashless exercise feature.

Our warrant activity during the years ended December 31, 2015 and 2014 is shown below (in thousands except price data):

	December 31,
	2015				2014
	Number		WAvg Exercise Price		Number		WAvg Exercise Price
Outstanding, beginning		60	$	7.98		431	$	15.75
Issued		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		(371)		17.00
Modification		-		(5.46)		-		-
Outstanding, ending		60	$	2.52		60	$	7.98

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

EMPLOYEE BENEFIT PLANS

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

EMPLOYEE BENEFIT PLANS

NOTE 11 – EMPLOYEE BENEFIT PLANS

401(k) and Profit-Sharing Plan

We have a 401(k) and Profit-Sharing Plan (the “Plan”) for our employees. Employees may elect to make a basic contribution of up to 80% of their annual earnings subject to certain regulatory restrictions on their total contribution. The Plan provides that the Company can make discretionary matching contributions along with a discretionary profit-sharing contribution. We did not contribute a matching contribution or a profit sharing contribution to the Plan in years 2015 or 2014.

Stock Option Plans

We maintain various stock option plans. A summary of our stock option plans as of December 31, 2015 and 2014 and for the years then ended consisted of the following (in thousands except per price data):

	Years Ended December 31,
	2015				2014
	Number of Options		Weighted Average Exercise Price		Number of Options		Weighted Average Exercise Price
Outstanding, beginning		911	$	20.70		747	$	24.95
Granted		315		2.01		180		2.60
Exercised		-		-		(6)		6.50
Forfeited or expired		(28)		26.75		(10)		17.50
Outstanding, ending		1,198	$	15.67		911	$	20.70
Options exercisable		814	$	22.04		695	$	26.05

The following table summarizes information about nonvested stock options outstanding at December 31, 2015 (in thousands except per price data):

	Number of Options Not Exercisable		Weighted Average FairValue
Outstanding at December 31, 2014		216	$	3.30
Granted		315		2.01
Vested		(146)		3.70
Forfeited		(1)		2.69
Outstanding at December 31, 2015		384	$	1.85

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date.

The assumptions used in the Black-Scholes model to determine fair value for the 2015 and 2014 stock option grants were:

	2015			2014
Expected dividend yield		0.0	%		0.0	%
Risk-free interest rates		2.2	%		2.2	%
Average expected volatility		89	%		97	%
Expected term (years)		10			10
Weighted average grant date fair value	$	1.72		$	2.30

The intrinsic value of the option awards which were vested and outstanding at December 31, 2015 was less than $10 thousand. The total remaining unrecognized compensation cost on unvested option awards outstanding at December 31, 2015 was $0.7 million, and is expected to be recognized in operating expense in varying amounts over the twenty-three months remaining in the requisite service period.

Information about the cashless stock option exercises during the last two years is as follows:

There were no option awards exercised during 2015.

During 2014, options to purchase 5 thousand shares of common stock were exercised utilizing various cashless exercise features of our stock option plan and after withholding 3 thousand shares for $32 in exercise costs and $1 in statutory minimum withholding payroll taxes, we issued 2 thousand shares of common stock.

Restricted Stock Unit Award Plan

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.

A summary of the grants under the RSU Plans as of December 31, 2015 and 2014, and for the years then ended consisted of the following (in thousands):

	Years Ended December 31,
	2015				2014
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs
Outstanding, beginning		29		29		166		166
Granted		42		-		29		-
Distributed		(26)		(26)		(166)		(166)
Vested		-		42		-		29
Forfeited or expired		-		-		-		-
Outstanding, ending		45		45		29		29

2005 Restricted Stock Unit Award Plan

Under our 2005 RSU Plan, one-fourth of vested shares of common stock underlying the aggregate RSU awards of 660 thousand shares, or 165 thousand shares, were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of the years 2011 thru 2014. On January 1, 2014, 102 thousand shares were distributed to the holders while 63 thousand shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $0.5 million withholding tax obligations. All RSUs granted under the 2005 RSU Plan had been distributed effective January 1, 2014.

2014 Restricted Stock Unit Award Plan

Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of December 31, 2015, 330 thousand shares are available for award under the 2014 RSU Plan.

Information about the awards under the 2014 RSU Plan is as follows:

	·	On May 1, 2014, we awarded approximately 7 thousand RSUs to each of our 4 non-employee directors. Such RSU awards vested 50% on June 30, 2014 and 25% on each of September 30 and December 31, 2014. Such non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet. The liability was $26 thousand at December 31, 2014. Accordingly the vested portion of the awards containing the cash settlement feature are being marked-to-market each reporting period until they are distributed. Marked-to-market accounting can create fluctuations in our compensation expense including the need to record additional expense. RSU awards are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

On January 2, 2015, we awarded approximately 10 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting and the liability recorded in the Company’s balance sheet was $45 thousand at December 31, 2015. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards was distributed on January 4, 2016.

Information about the distribution of shares under the 2014 RSU Plan is as follows:

	·	On January 2, 2015, 26 thousand RSUs from the May 1, 2014 award were distributed and 4 thousand RSUs were deferred until a future distribution date. Of the 26 thousand RSUs distributed, 19 thousand RSUs were distributed in common stock and 7 thousand RSUs were settled in cash.

On January 4, 2016, 1 thousand RSUs from the May 1, 2014 award and 41 thousand RSUs from the January 2, 2015 award were distributed. There are 2 thousand RSUs from the May 1, 2014 award which remain deferreded until a future distribution date. Of the 42 thousand RSUs distributed, 33 thousand RSUs were distributed in common stock and 9 thousand RSUs were settled in cash.

INCOME TAXES

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

Provision for Income Taxes

The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands):

	December 31,
	2015		2014
Benefit at U.S. statutory 34% tax rate	$	(1,696)	$	(4,491)
State taxes (benefit), net of federal effect		41		65
Research and development tax credits		-		(30)
Share-based compensation		184		262
Other		11		2
Change in valuation allowance		1,460		4,192
Provision for income taxes	$	-	$	-

Deferred Tax Assets and Valuation Allowance

Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $52.8 million federal income tax benefits at December 31, 2015 derived from $155.2 million Federal NOLs at the U.S. statutory tax rate of 34% and $2.0 million state NOLs, available to offset future taxable income, some of which already have limitations for future use as prescribed under IRC Section 382. Our Federal and state NOLs will expire in varying amounts between 2016 and 2035 if not used, and those expirations will cause fluctuations in our valuation allowances. The net change in the valuation allowance in 2015 and 2014 was approximately $0.6 million and $2.4 million, respectively.

As of December 31, 2015 we had federal research and development tax credits of approximately $1.2 million, which expire in the years 2024 through 2034. We also had approximately $0.2 million of Indiana state research and development tax credits, which expire in the years 2016 and 2017. The components of our deferred tax assets are as follows:

	December 31,
	2015		2014

	(in thousands)
Deferred tax assets:
Estimated future value of NOLs
- Federal	$	52,772	$	51,503
- State		2,050		2,898
Research and development tax credits		1,394		1,398
Share-based compensation		38		45
Other, net		368		151
Total deferred taxes		56,622		55,995
Valuation allowance		(56,622)		(55,995)
Net deferred tax assets	$	-	$	-

Realization of deferred tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. Valuation allowances are placed on deferred tax assets when uncertainty exists on their near term utilization. We make periodic reviews of our valuation allowances and fluctuations can occur. Those fluctuations may be reflected as income tax expenses or benefits in the period they occur. We continue to maintain full valuation allowance against all of our deferred tax assets at December 31, 2015 due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that amounts of our deferred tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and a benefit from income taxes in such period would be recognized.

Uncertainty in Income Taxes

We adopted FASB’s statement regarding accounting for uncertainty in income taxes which defined the threshold for recognizing the benefits of tax-return positions in the consolidated financial statements as "more-likely-than-not" to be sustained by the taxing authorities. Our adoption of the standard did not result in establishing a contingent tax liability reserve or a corresponding charge to retained earnings. At each of December 31, 2015 and 2014, we had no liability for income tax associated with uncertain tax positions. If in the future we establish a contingent tax liability reserve related to uncertain tax positions, our practice will be to recognize the interest in interest expense and the penalties in other non-operating expense.

The Company files federal and state income tax returns and in the normal course of business the Company is subject to examination by these taxing authorities. As of December 31, 2015, the Company’s tax years 2012, 2013 and 2014 are subject to examination by the taxing authorities. With few exceptions, we believe the Company is no longer subject to U.S. federal, state and local examinations by taxing authorities for years before 2012.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Purdue Pharma Complaints

In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “’007 patent”). The complaint seeks injunctive relief as well as awards of damages and attorneys’ fees. In January 2016, the District Court issued a claim construction order in the patent infringement action. The order stated that the term polyvinylpyrrolidone as that term is defined in the claims of the Purdue patent covers all polymeric forms of vinylpyrrolidone, including crospovidone used in Oxaydo. We deny the allegations in the complaint, believe they are without merit and are defending the action vigorously. As is the case with patent litigation, there is a risk that the Court may enjoin the making, using, selling and offering for sale Oxaydo and/or may find that Oxaydo infringes the ‘007 patent. As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to this matter as of December 31, 2015.

In December 2014, the Company entered into an agreement with Purdue Pharma L.P. to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby the Company conceded Purdue Pharma’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue Pharma relating to the December 2014 agreement.

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

In the Pennsylvania action, over 200 lawsuits have been filed against Acura and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 89 pending cases against us, with more than 445 individual plaintiffs.

In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by Acura. We discontinued manufacture and distribution of generic metoclopramide more than 18 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases.

In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. In June 2012, the New Jersey trial court dismissed all of the New Jersey cases pending against Acura with prejudice. It is possible that this ruling may eventually be appealed by plaintiffs at the conclusion of the litigation in the trial court.

In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing decision.

In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al., No. 14-711 (U.S.) seeking reversal of the Pennsylvania state court decision. On April 27, 2015, the U.S. Supreme Court denied this Petition and this matter has been returned to the trial court for further proceedings. From July, 2015 to date, the court has been moving forward with procedural steps to narrow this litigation, including requests for plaintiffs to voluntarily discontinue cases, such as those filed against Acura, where there is no case-specific product identification. To the extent, however, that plaintiffs intend to pursue these claims, Acura nonetheless remains optimistic that most, if not all, of these Philadelphia cases will eventually be dismissed against it based upon the favorable aspects of the Superior Court’s narrow preemption ruling and lack of product identification, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by Acura’s insurance carrier.

In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett decision. Thus far, Acura and most Generic Defendants have not been required to file answers or other responsive pleadings in each individual case in which they are named defendants. However, the individual cases against Acura have been stayed pending resolution of certain jurisdictional issues relating to cases filed by non-resident California plaintiffs and further action by the trial court. Subject to further developments, plaintiffs may be permitted to proceed with these lawsuits against Acura including state law claims based on (1) failing to communicate warnings to physicians through “Dear Doctor” letters; and (2) failure to update labeling to adopt brand labeling changes. The California trial court also has acknowledged the preemptive effect of Mensing so that any claim “that would render the generic defendants in violation of federal law if they are found responsible under a state law cause of action, would not be permissible.” To date, however, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by Acura. Therefore, we expect the number of plaintiffs with possible claims to be reduced voluntarily or by motion practice. Action will be taken in an effort to dismiss Acura from these cases, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.

As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of December 31, 2015 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.

Paragraph IV ANDA Litigation and License Grants

On or about September 17, 2012, the FDA began accepting Abbreviated New Drug Applications, or ANDAs, referencing Oxaydo. To date, we have received Paragraph IV Certification Notices under 21 U.S.C. 355(j) (a Paragraph IV Notice) from five separate generic sponsors of an ANDA for a generic drug listing Oxaydo as the reference listed drug. The Paragraph IV Notices state that each generic sponsor believes that our Aversion Technology patents listed in FDA’s Orange Book are invalid, unenforceable or not infringed. We initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc., and Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book.

We dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry.

We have entered into distinct Settlement Agreements with each of Par, Impax, Ranbaxy and Sandoz to settle our patent infringement actions. Par is the first filer of an ANDA for a generic Oxaydo product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations. Par is entitled to launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025. In certain limited circumstances, our license to Par would become effective prior to January 1, 2022. Par is required to pay us royalties in the range of 10% to 15% of Par’s net profits from the sale of its generic Oxaydo product.

Impax and Sandoz are entitled to launch their generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxaydo product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxaydo product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax and Sandoz would become effective prior to such time. In certain circumstances, Sandoz may be required to pay us a royalty on net profits of their generic Oxaydo product.

Our Settlement Agreement with Ranbaxy provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product.

Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

Facility Lease

The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2017 for approximately $25 thousand annually.

SUPPLEMENTARY DATA (UNAUDITED)

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31, 2015		June 30, 2015		Sept. 30, 2015		Dec. 31, 2015
Net revenues	$	5,357	$	341	$	210	$	2,679
Operating expenses		3,845		2,739		2,615		3,389

Operating income (loss)		1,512		(2,398)		(2,405)		(710)
Net income (loss)	$	1,239	$	(2,663)	$	(2,649)	$	(916)

Basic income (loss) per share	$	0.13	$	(0.28)	$	(0.23)	$	(0.08)
Diluted income (loss) per share	$	0.13	$	(0.28)	$	(0.23)	$	(0.08)

	For Three Month Periods Ended
	Mar. 31, 2014		June 30, 2014		Sept. 30, 2014		Dec. 31, 2014
Net revenues	$	42	$	35	$	145	$	529
Operating expenses		3,868		3,307		2,791		2,984

Operating loss		(3,826)		(3,272)		(2,646)		(2,455)
Net loss	$	(4,088)	$	(3,521)	$	(2,904)	$	(2,696)

Basic loss per share	$	(0.40)	$	(0.35)	$	(0.30)	$	(0.30)
Diluted loss per share	$	(0.40)	$	(0.35)	$	(0.30)	$	(0.30)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Reclassifications

Reclassifications

Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation.

Management Estimates

Management Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Marketable Securities

Marketable Securities

Fair Value of Other Financial Instruments

Fair Value of Other Financial Instruments

Concentration of Credit Risk

Concentration of Credit Risk

Customer	2015			2014
Rite Aid Corporation		54	%		28	%
Cardinal Health, Inc.		14	%		24	%
AmerisourceBergen Corporation		*			13	%
McKesson Corporation		*			13	%
Kroger Foods		*			11	%

Customer	2015			2014
Rite Aid Corporation		68	%		83	%
McKesson Corporation		11	%		**
Kroger Foods		**			13	%

Inventories

Inventories

Property, Plant and Equipment

Property, Plant and Equipment

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

Debt Issuance Costs and Debt Discount

Debt Issuance Costs and Debt Discount

License Fees

License Fees

In December 2014, the Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue relating to the December 2014 agreement.

On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) entered into a Collaboration and License Agreement to commercialize Oxaydo tablets (formerly known as Oxecta) utilizing our Aversion® Technology. Egalet paid us an upfront payment of $5.0 million upon signing the Egalet Agreement (see Note 3).

Milestone Revenue

Milestone Revenue

Collaboration Revenue

Collaboration Revenue

Royalty Revenue

Royalty Revenue

Product Sales

Product Sales

Advertising Costs

Advertising Costs

The Company records the cost of its advertising efforts when services are performed or goods are delivered.

Shipping and Handling Costs

Shipping and Handling Costs

The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Research and Development Activities

Research and Development Activities

Share-based Compensation

Share-based Compensation

We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11.

Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands):

	Year ended December 31,
	2015		2014
Research and development:
Stock option awards	$	158	$	220
RSU awards		-		-
	$	158	$	220

Selling, general and administrative:
Stock option awards		384		550
RSU awards		95		146
	$	479	$	696

Total share-based compensation expense	$	637	$	916

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Income Taxes

Income Taxes

Earnings Per Share (“EPS”)

Earnings Per Share (“EPS”)

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands, except per share data):

	Years ended December 31,
	2015		2014
EPS – basic
Numerator: net loss	$	(4,989)	$	(13,209)
Denominator (weighted):
Common shares		10,777		9,770
Vested RSUs		19		9
Basic weighted average shares outstanding		10,796		9,779
EPS - basic	$	(0.46)	$	(1.35)

EPS – assuming dilution
Numerator: net loss	$	(4,989)	$	(13,209)
Denominator (weighted):
Common shares		10,777		9,770
Vested RSUs		19		9
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		10,796		9,779
EPS - diluted	$	(0.46)	$	(1.35)

Excluded dilutive securities:
Common stock issuable (non weighted):
Stock options		1,198		911
Common stock warrants		60		60
Total excluded potentially dilutive shares		1,258		971

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Revenue from Contracts with Customers

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

Presentation of Debt Issuance Costs

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Concentration of Risk, by Risk Factor

Customer	2015			2014
Rite Aid Corporation		54	%		28	%
Cardinal Health, Inc.		14	%		24	%
AmerisourceBergen Corporation		*			13	%
McKesson Corporation		*			13	%
Kroger Foods		*			11	%

Customer	2015			2014
Rite Aid Corporation		68	%		83	%
McKesson Corporation		11	%		**
Kroger Foods		**			13	%

Estimated Lives of Major Classification of Depreciable Assets

The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

Non-Cash Share-Based Compensation Expense

Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands):

	Year ended December 31,
	2015		2014
Research and development:
Stock option awards	$	158	$	220
RSU awards		-		-
	$	158	$	220

Selling, general and administrative:
Stock option awards		384		550
RSU awards		95		146
	$	479	$	696

Total share-based compensation expense	$	637	$	916

Computation of Diluted Earnings (loss) Per Share

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands, except per share data):

	Years ended December 31,
	2015		2014
EPS – basic
Numerator: net loss	$	(4,989)	$	(13,209)
Denominator (weighted):
Common shares		10,777		9,770
Vested RSUs		19		9
Basic weighted average shares outstanding		10,796		9,779
EPS - basic	$	(0.46)	$	(1.35)

EPS – assuming dilution
Numerator: net loss	$	(4,989)	$	(13,209)
Denominator (weighted):
Common shares		10,777		9,770
Vested RSUs		19		9
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		10,796		9,779
EPS - diluted	$	(0.46)	$	(1.35)

Excluded dilutive securities:
Common stock issuable (non weighted):
Stock options		1,198		911
Common stock warrants		60		60
Total excluded potentially dilutive shares		1,258		971

INVESTMENTS IN MARKETABLE SECURITIES (Tables)

12 Months Ended

Dec. 31, 2015

Investments, Debt and Equity Securities [Abstract]

Marketable securities

Investments in marketable securities consisted of the following (in millions):

	December 31, 2015		December 31, 2014
Marketable securities:
Corporate bonds — maturing within 1 year	$	3.1	$	3.5
Corporate bonds — maturing after 1 year and through March 2017		0.4		2.8
Exchange-traded funds		7.3		5.0
Total marketable securities	$	10.8	$	11.3

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	December 31, 2015
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	3.6	$	-	$	(0.1)	$	3.5
Exchange-traded funds		7.3		-		-		7.3
Total - Current	$	10.9	$	-	$	(0.1)	$	10.8

	December 31, 2014
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

Fair Value, Assets Measured on Recurring Basis

Our assets measured at fair value or disclosed at fair value on a recurring basis as at December 31, 2015 and 2014 consisted of the following (in millions):

	December 31, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		3.5		-		3.5		-
Exchange-traded funds		7.3		7.3		-		-
Total	$	10.8	$	7.3	$	3.5	$	-

	December 31, 2014
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds		6.3		-		6.3		-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3	$	5.0	$	6.3	$	-

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2015

Inventory Disclosure [Abstract]

Inventories

Inventories are summarized as follows (in thousands):

	December 31,
	2015		2014
Raw and packaging	$	-	$	260
Finished goods		346		44
Total inventory		346		304
Less: inventory reserve - finished goods		(70)		(-)
Net inventory	$	276	$	304

Inventory Reserve

Inventory reserve activity during the years ended December 31, 2015 and 2014 was as follows (in thousands):

	2015		2014
Beginning of year	$	-	$	250
Reserve expense - raw and packaging		260		-
Reserve expense - finished goods		70		201
		330		451
Inventory write-offs - raw and packaging		(260)		-
Inventory write-offs - finished goods		-		(451)
End of year	$	70	$	-

DEBT (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Schedule of Debt

Our debt is summarized below (in thousands):

Long-term Debt	Current		Long-term		Total
Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
Principal payments		(1,960)		-		(1,960)
Classification		2,522		(2,522)		-
Balance at Dec 31, 2015	$	2,320	$	5,720	$	8,040

Debt Discount	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(281)	$	(281)
Modification of warrants		-		(33)		(33)
Amortization expense		-		121		121
Balance at Dec 31, 2015	$	-	$	(193)	$	(193)

Deferred Debt Issuance Costs	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(162)	$	(162)
Amortization expense		-		65		65
Balance at Dec 31, 2015	$	-	$	(97)	$	(97)

Long-term Debt, net at Dec 31, 2015	$	2,320	$	5,430	$	7,750

Schedule Of Fair Value Of Warrants

The fair value of the warrants was determined using the Black-Scholes option-pricing model. Significant assumptions used in the Black-Scholes model were:

Expected dividend yield	0.0	%
Risk-free interest rate	2.4	%
Expected volatility	92	%
Expected term (years)	7

Schedule of Interest Expense

Our interest expense consisted of the following (in thousands):

	2015		2014
Interest expense:
Term Loan	$	971	$	1,024
Debt discount		121		119
Debt issue costs		65		69
Total interest expense	$	1,157	$	1,212

Schedule Of Long Term Debt Future Principal Payments Year

The annual principal payments of the debt at December 31, 2015 are as follows:

	Annual Principal Payments
Year	(in thousands)
2016	$	2,320
2017		2,741
2018		2,979
Total	$	8,040

COMMON STOCK WARRANTS (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders Equity Note [Abstract]

Schedule Of Common Stock Warrant Activity

Our warrant activity during the years ended December 31, 2015 and 2014 is shown below (in thousands except price data):

	December 31,
	2015				2014
	Number		WAvg Exercise Price		Number		WAvg Exercise Price
Outstanding, beginning		60	$	7.98		431	$	15.75
Issued		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		(371)		17.00
Modification		-		(5.46)		-		-
Outstanding, ending		60	$	2.52		60	$	7.98

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

EMPLOYEE BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

	Years Ended December 31,
	2015				2014
	Number of Options		Weighted Average Exercise Price		Number of Options		Weighted Average Exercise Price
Outstanding, beginning		911	$	20.70		747	$	24.95
Granted		315		2.01		180		2.60
Exercised		-		-		(6)		6.50
Forfeited or expired		(28)		26.75		(10)		17.50
Outstanding, ending		1,198	$	15.67		911	$	20.70
Options exercisable		814	$	22.04		695	$	26.05

Schedule of Nonvested Share Activity

The following table summarizes information about nonvested stock options outstanding at December 31, 2015 (in thousands except per price data):

	Number of Options Not Exercisable		Weighted Average Fair Value
Outstanding at December 31, 2014		216	$	3.30
Granted		315		2.01
Vested		(146)		3.70
Forfeited		(1)		2.69
Outstanding at December 31, 2015		384	$	1.85

Schedule of fair value of the warrants

The assumptions used in the Black-Scholes model to determine fair value for the 2015 and 2014 stock option grants were:

	2015			2014
Expected dividend yield		0.0	%		0.0	%
Risk-free interest rates		2.2	%		2.2	%
Average expected volatility		89	%		97	%
Expected term (years)		10			10
Weighted average grant date fair value	$	1.72		$	2.30

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans as of December 31, 2015 and 2014, and for the years then ended consisted of the following (in thousands):

	Years Ended December 31,
	2015				2014
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs
Outstanding, beginning		29		29		166		166
Granted		42		-		29		-
Distributed		(26)		(26)		(166)		(166)
Vested		-		42		-		29
Forfeited or expired		-		-		-		-
Outstanding, ending		45		45		29		29

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Provision for Income Taxes

The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands):

	December 31,
	2015		2014
Benefit at U.S. statutory 34% tax rate	$	(1,696)	$	(4,491)
State taxes (benefit), net of federal effect		41		65
Research and development tax credits		-		(30)
Share-based compensation		184		262
Other		11		2
Change in valuation allowance		1,460		4,192
Provision for income taxes	$	-	$	-

Components Of Deferred Tax Assets

	December 31,
	2015		2014

	(in thousands)
Deferred tax assets:
Estimated future value of NOLs
- Federal	$	52,772	$	51,503
- State		2,050		2,898
Research and development tax credits		1,394		1,398
Share-based compensation		38		45
Other, net		368		151
Total deferred taxes		56,622		55,995
Valuation allowance		(56,622)		(55,995)
Net deferred tax assets	$	-	$	-

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Selected unaudited quarterly consolidated financial data

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31, 2015		June 30, 2015		Sept. 30, 2015		Dec. 31, 2015
Net revenues	$	5,357	$	341	$	210	$	2,679
Operating expenses		3,845		2,739		2,615		3,389

Operating income (loss)		1,512		(2,398)		(2,405)		(710)
Net income (loss)	$	1,239	$	(2,663)	$	(2,649)	$	(916)

Basic income (loss) per share	$	0.13	$	(0.28)	$	(0.23)	$	(0.08)
Diluted income (loss) per share	$	0.13	$	(0.28)	$	(0.23)	$	(0.08)

	For Three Month Periods Ended
	Mar. 31, 2014		June 30, 2014		Sept. 30, 2014		Dec. 31, 2014
Net revenues	$	42	$	35	$	145	$	529
Operating expenses		3,868		3,307		2,791		2,984

Operating loss		(3,826)		(3,272)		(2,646)		(2,455)
Net loss	$	(4,088)	$	(3,521)	$	(2,904)	$	(2,696)

Basic loss per share	$	(0.40)	$	(0.35)	$	(0.30)	$	(0.30)
Diluted loss per share	$	(0.40)	$	(0.35)	$	(0.30)	$	(0.30)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk by Risk Factor (Detail)

12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Sales Revenue, Net

Concentration Risk [Line Items]

Concentration Risk, Percentage

10.00%

Accounts Receivable [Member]

Concentration Risk [Line Items]

Concentration Risk, Percentage

10.00%

Rite Aid Corporation | Sales Revenue, Net

Concentration Risk [Line Items]

Concentration Risk, Percentage

54.00%

28.00%

Rite Aid Corporation | Accounts Receivable [Member]

Concentration Risk [Line Items]

Concentration Risk, Percentage

68.00%

83.00%

Cardinal Health, Inc. | Sales Revenue, Net

Concentration Risk [Line Items]

Concentration Risk, Percentage

14.00%

24.00%

AmerisourceBergen Corporation | Sales Revenue, Net

Concentration Risk [Line Items]

Concentration Risk, Percentage

0.00%

^[1]

13.00%

McKesson Corporation | Sales Revenue, Net

Concentration Risk [Line Items]

Concentration Risk, Percentage

0.00%

^[1]

13.00%

McKesson Corporation | Accounts Receivable [Member]

Concentration Risk [Line Items]

Concentration Risk, Percentage

11.00%

0.00%

^[2]

Kroger Foods | Sales Revenue, Net

Concentration Risk [Line Items]

Concentration Risk, Percentage

0.00%

^[1]

11.00%

Kroger Foods | Accounts Receivable [Member]

Concentration Risk [Line Items]

Concentration Risk, Percentage

0.00%

^[2]

13.00%

[1]	accounted for less than 10% of our annual product sales.
[2]	accounted for less than 10% of our gross accounts receivable.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of the Major Classification of Depreciable Assets (Detail)	12 Months Ended
	Dec. 31, 2015
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Land Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Land Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Scientific Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Scientific Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Non-Cash Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 637	$ 916
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	158	220
Research and Development Expense \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	158	220
Research and Development Expense \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	0	0
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	479	696
Selling, General and Administrative \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	384	550
Selling, General and Administrative \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 95	$ 146

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
EPS - basic
Numerator: net loss	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (4,989)	$ (13,209)
Denominator (weighted):
Common shares									10,777	9,770
Vested RSUs									19	9
Basic weighted average shares outstanding									10,796	9,779
EPS - basic	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)
EPS - assuming dilution
Numerator: net loss	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (4,989)	$ (13,209)
Denominator (weighted):
Common shares									10,777	9,770
Vested RSUs									19	9
Stock options									0	0
Common stock warrants									0	0
Diluted weighted average shares outstanding									10,796	9,779
EPS - diluted	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									1,258	971
Common stock warrants [Member]
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									60	60
Employee Stock Option [Member]
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									1,198	911

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 09, 2014	Oct. 31, 2015	Jun. 30, 2015	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Financing Receivable, Impaired [Line Items]
Deferred Revenue, Revenue Recognized							$ 353
Royalty Revenue, Total						$ 5	4
Other Revenue, Net						170	0
Sales Revenue, Goods, Net, Total				$ 314	$ 314	662	247
Revenue Recognition, Sales Returns, Reserve for Sales Returns				120	120	205
Related Parties Amount in Cost of Sales				$ 255	$ 255
Professional and Contract Services Expense						$ 200	100
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets							$ 162
Egalet Ltd [Member]
Financing Receivable, Impaired [Line Items]
Loss Contingency, Settlement Agreement, Terms						Egalet paid us an upfront payment of $5.0 million upon signing the Egalet Agreement
Proceeds from Milestone Payment On Agreement		$ 2,500
Sales Revenue, Net [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%
Sales Revenue, Net [Member] \| Minimum [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%	10.00%
Accounts Receivable [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%
Accounts Receivable [Member] \| Minimum [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%	10.00%
Purdue Pharma [Member]
Financing Receivable, Impaired [Line Items]
Litigation Settlement, Expense			$ 250				$ 500
Pfizer [Member]
Financing Receivable, Impaired [Line Items]
Contract Termination Claims, Description	Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer
Pfizer [Member] \| Raw Materials [Member]
Financing Receivable, Impaired [Line Items]
Payments to Suppliers							$ 260

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Oct. 09, 2015	Dec. 31, 2015	Dec. 31, 2014
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description		Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
Retail Related Inventory, Total		$ 260
Amortization of Intangible Assets		207	$ 155
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Payment for Termination		$ 2,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Minimum Net Sales Reaching Description		one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Licenses Revenue	$ 5,000
Proceeds from Milestone Payment On Agreement	$ 2,500

INVESTMENTS IN MARKETABLE SECURITIES - Summary of Investments in Marketable Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Marketable securities:
Corporate bonds - maturing within 1 year	$ 3.1	$ 3.5
Corporate bonds - maturing after 1 year and through March 2017	0.4	2.8
Total marketable securities	10.8	11.3
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 7.3	$ 5.0

INVESTMENTS IN MARKETABLE SECURITIES - Fair Value and Unrealized Gains (Losses) related to the Company’s Available-For-Sale Securities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Available-for-sale:
Cost	$ 10.9	$ 11.3
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	(0.1)	0.0
Fair Value	10.8	11.3
Corporate Bonds
Available-for-sale:
Cost	3.6	6.3
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	(0.1)	0.0
Fair Value	3.5	6.3
Exchange-traded funds
Available-for-sale:
Cost	7.3	5.0
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	$ 7.3	$ 5.0

INVESTMENTS IN MARKETABLE SECURITIES - Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Assets:
Total marketable securities	$ 10.8	$ 11.3
Corporate bonds
Assets:
Total marketable securities	3.5	6.3
Exchange-traded funds
Assets:
Total marketable securities	7.3	5.0
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	3.5	6.3
Fair Value, Inputs, Level 1 \| Corporate bonds
Assets:
Total marketable securities	3.5	6.3
Fair Value, Inputs, Level 1 \| Exchange-traded funds
Assets:
Total marketable securities	0.0	0.0
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	0.0	0.0
Fair Value, Inputs, Level 2 \| Corporate bonds
Assets:
Total marketable securities	0.0	0.0
Fair Value, Inputs, Level 2 \| Exchange-traded funds
Assets:
Total marketable securities	0.0	0.0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	7.3	5.0
Fair Value, Inputs, Level 3 \| Corporate bonds
Assets:
Total marketable securities	0.0	0.0
Fair Value, Inputs, Level 3 \| Exchange-traded funds
Assets:
Total marketable securities	$ 7.3	$ 5.0

INVENTORIES - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw and packaging	$ 0	$ 260
Finished goods	346	44
Total inventory	346	304
Less: inventory reserve - finished goods	(70)	0	$ (250)
Net inventory	$ 276	$ 304

INVENTORIES - Inventory Reserve (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Beginning of year	$ 0	$ 250
Reserve expense - raw and packaging	260	0
Reserve expense - finished goods	70	201
Inventory Reserve Expense	330	451
Inventory write-offs - raw and packaging	(260)	0
Inventory write-offs - finished goods	0	(451)
End of year	$ 70	$ 0

INVENTORIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross	$ 0		$ 0	$ 260
Deferred Revenue, Current	0		0	353
Sales Revenue, Goods, Net, Total	314	$ 314	662	247
Revenue Recognition, Sales Returns, Reserve for Sales Returns	120	120	$ 205
Related Parties Amount in Cost of Sales	$ 255	$ 255
Nexafed products [Member]
Inventory [Line Items]
Cost of Goods Sold				218
Deferred Revenue, Current				$ 350

PROPERTY, PLANT AND EQUIPMENT (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,754	$ 2,751
Less: accumulated depreciation	(1,741)	(1,794)
Total property, plant and equipment, net	1,013	957
Building and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,265	1,259
Scientific equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	598	595
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	124	252
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	508	386
Land and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 27	$ 27

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Line Items]
Professional services	$ 171	$ 253
Other fees and services	64	110
Payroll, payroll taxes and benefits	101	94
Clinical and regulatory services	92	83
Marketing, advertising, and promotion	115	0
Property taxes	15	15
Franchise taxes	6	13
Total	$ 564	$ 568

DEBT - Fair Value of Warrants using the Black-Scholes option-pricing model - (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Of Warrants [Line Items]
Expected dividend yield	0.00%	0.00%
Risk-free interest rates	2.40%	2.20%
Average expected volatility	92.00%	97.00%
Expected term (years)	7 years	10 years

DEBT - Summary of Debt (Detail) - USD ($) $ in Thousands		12 Months Ended
DEBT - Summary of Debt (Detail) - USD ($) $ in Thousands	Jan. 07, 2015	Dec. 31, 2015
Long-term Debt
Balance at Dec 31, 2014	$ 10,000	$ 10,000
Principal payments		(1,960)
Classification		0
Balance at Dec 31, 2015		8,040
Debt Discount
Balance at Dec 31, 2014	(281)	(281)
Modification of warrants	33	33
Amortization expense		121
Balance at Dec 31, 2015		(193)
Deferred Debt Issuance Costs
Balance at Dec 31, 2014	(162)	(162)
Amortization expense		65
Balance at Dec 31, 2015		(97)
Long-term Debt, net at Dec 31, 2015		7,750
Long-term [Member]
Long-term Debt
Balance at Dec 31, 2014	8,242	8,242
Principal payments		0
Classification		(2,522)
Balance at Dec 31, 2015		5,720
Debt Discount
Balance at Dec 31, 2014	(281)	(281)
Modification of warrants		(33)
Amortization expense		121
Balance at Dec 31, 2015		(193)
Deferred Debt Issuance Costs
Balance at Dec 31, 2014	(162)	(162)
Amortization expense		65
Balance at Dec 31, 2015		(97)
Long-term Debt, net at Dec 31, 2015		5,430
Current [Member]
Long-term Debt
Balance at Dec 31, 2014	1,758	1,758
Principal payments		(1,960)
Classification		2,522
Balance at Dec 31, 2015		2,320
Debt Discount
Balance at Dec 31, 2014	0	0
Modification of warrants		0
Amortization expense		0
Balance at Dec 31, 2015		0
Deferred Debt Issuance Costs
Balance at Dec 31, 2014	$ 0	0
Amortization expense		0
Balance at Dec 31, 2015		0
Long-term Debt, net at Dec 31, 2015		$ 2,320

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Interest expense:
Term Loan	$ 971	$ 1,024
Debt discount	121	119
Debt issue costs	65	69
Total interest expense	$ 1,157	$ 1,212

DEBT - Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
2016	$ 2,320
2017	2,741
2018	2,979
Total	$ 8,040	$ 10,000

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
	Jan. 07, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount				$ 10,000
Debt instrument, interest rate, stated percentage				8.35%
Debt default long term debt percentage				13.35%
Debt Instrument, Maturity Date		Dec. 01, 2018
Debt instrument, fee amount		$ 50
Debt consulting placement fee		100
Debt related commitment fees and debt issuance costs		231
Debt instrument unamortized discount		$ 193	$ 281
Warrants to purchase common stock		60
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.52
Debt instrument Cash Maintenance	$ 2,500
Repayments of Debt	5,000	$ 1,960	$ 0
Additions To Debt Instrument Unamortized Discount	$ 33	33
Debt Instrument, Periodic Payment		260
Debt instrument, periodic payment, principal		$ 1,960
Debt Instrument, Interest Rate, Effective Percentage		10.16%
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98	$ 7.98
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52	$ 2.52
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount		$ 400
Warrants to purchase common stock		60
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 7.98
Warrants, expiry date		December 27, 2020
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid		$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage		1.00%

EQUITY FINANCINGS - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 18, 2013	Jun. 30, 2015	Dec. 31, 2015
Equity Financing [Line Items]
Proceeds from sale of common stock	$ 13,000
Sale leaseback transaction, transaction costs, financing activities			$ 8
Sale leaseback transaction, net proceeds, financing activities			$ 217
Placement agency reimbursed for expenses		$ 496
Common Stock, Par or Stated Value Per Share			$ 0.01
Common Stock [Member]
Equity Financing [Line Items]
Proceeds from sale of common stock			$ 225
Stock issued during period, shares, new issues			54
Placement Agency Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues		1,958
Share price		$ 0.01
Proceeds from issuance of private placement		$ 7,000
Description for repayment of placement agent		paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering
Placement agency reimbursed for expenses		$ 35
Common Stock, Par or Stated Value Per Share		$ 01
Securities Purchase Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues		1,958
Share price		$ 3.90
Proceeds from issuance of private placement		$ 7,640

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Number of Options
Number of Options Outstanding, beginning	60	431
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	(371)
Number of Options Outstanding, ending	60	60
Number of Options, Modification	0	0
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 7.98	$ 15.75
Issued	0	0
Exercised	0	0
Expired	0	17.00
Modification	(5.46)	0
Weighted Average Exercise Price, ending	$ 2.52	$ 7.98

COMMON STOCK WARRANTS - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Secured Debt		$ 10.0
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Common stock Warrant expiration date	December 27, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98

EMPLOYEE BENEFIT PLANS - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	911	747
Number of Options, Granted	315	180
Number of Options, Exercised	0	(6)
Number of Options, Forfeited or expired	(28)	(10)
Number of Options Outstanding, ending	1,198	911
Number of Options exercisable	814	695
Weighted Average Exercise Price, beginning	$ 20.70	$ 24.95
Weighted Average Exercise Price, Granted	2.01	2.60
Weighted Average Exercise Price, Exercised	0	6.50
Weighted Average Exercise Price, Forfeited or expired	26.75	17.50
Weighted Average Exercise Price, ending	15.67	20.70
Weighted Average Exercise Price, Options exercisable	$ 22.04	$ 26.05

EMPLOYEE BENEFIT PLANS - Summary of Information about Non Vested Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning \| shares	216
Granted \| shares	315
Vested \| shares	(146)
Forfeited \| shares	(1)
Outstanding, ending \| shares	384
Outstanding beginning, Weighted Average Fair Value \| $ / shares	$ 3.30
Granted, Weighted Average Fair Value \| $ / shares	2.01
Vested, Weighted Average Fair Value \| $ / shares	3.70
Forfeited, Weighted Average Fair Value \| $ / shares	2.69
Outstanding ending, Weighted Average Fair Value \| $ / shares	$ 1.85

EMPLOYEE BENEFIT PLANS - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Risk-free interest rates	2.40%	2.20%
Average expected volatility	92.00%	97.00%
Expected term (years)	7 years	10 years
Weighted average grant date fair value	$ 1.72	$ 2.30

EMPLOYEE BENEFIT PLANS - Summary of RSU Plan (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	216
Granted	315
Vested	146
Forfeited or expired	1
Outstanding, ending	384	216
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	42	29
Distributed	(26)	(166)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	45	29
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	0	0
Distributed	(26)	(166)
Vested	42	29
Forfeited or expired	0	0
Outstanding, ending	45	29

EMPLOYEE BENEFIT PLANS - Additional Information (Detail) - USD ($)	1 Months Ended										8 Months Ended	12 Months Ended			20 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jan. 02, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	May. 01, 2014	Jan. 31, 2014	Jan. 02, 2015	Jan. 04, 2016	Dec. 31, 2015	Dec. 31, 2014	Jan. 04, 2016
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested	$ 6,000					$ 0							$ 6,000	$ 0
Unrecognized compensation cost on unvested option awards outstanding	711,000												$ 711,000
Common stock exercised in cashless exercise features														5,000
Withholding tax obligations														$ 32,000
Statutory Minimum Payroll Taxes														$ 1,000
Number Of Shares Issued On Cashless Exercises														2,000
Number of vested shares distributed to holders													146,000
Common stock exercised in cashless exercise features withheld minimum payroll taxes														3,000
401(k) and Profit-Sharing Plan
Employee Benefit Plans Disclosure [Line Items]
Maximum basic contribution percentage per employee on annual earnings													80.00%
2005 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Shares withheld upon elections made to exchange RSUs										63
Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations										$ 525
Number of vested shares distributed to holders										102
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														166,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights													one-fourth of vested shares of common stock underlying the aggregate RSU awards of 660 thousand shares, or 166 thousand shares, were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of the years 2011 thru 2014.
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant									400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											26,000
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution											4,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award													330,000
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 45,000												$ 45,000
2014 Restricted Stock Unit Award Plan [Member] \| Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											7,000
2014 Restricted Stock Unit Award Plan [Member] \| Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											26,000
2014 Restricted Stock Unit Award Plan [Member] \| Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											19,000
2014 Restricted Stock Unit Award Plan [Member] \| Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									7,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%	25.00%	25.00%	25.00%		25.00%	25.00%	50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description					stock, for up to 40%				stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value														$ 26,000
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period												41,000			1
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution															2
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member] \| Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period															9
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member] \| Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period															42
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member] \| Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period															33

INCOME TAXES - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Provision For Income Taxes [Line Items]
Benefit at U.S. statutory 34% tax rate	$ (1,696)	$ (4,491)
State taxes (benefit), net of federal effect	41	65
Research and development tax credits	0	(30)
Share-based compensation	184	262
Other	11	2
Change in valuation allowance	1,460	4,192
Provision for income taxes	$ 0	$ 0

INCOME TAXES - Components of Our Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
- Federal	$ 52,772	$ 51,503
- State	2,050	2,898
Research and development tax credits	1,394	1,398
Share-based compensation	38	45
Other, net	368	151
Total deferred taxes	56,622	55,995
Valuation allowance	(56,622)	(55,995)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 52,800
Federal NOLs	$ 155,200
U.S. statutory tax rate	34.00%
Research and development tax credits	$ 1,394	$ 1,398
State income tax benefits	2,000
Valuation allowance, deferred tax asset, change in amount	600	$ 2,400
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 1,200
Research and development expiration period	which expire in the years 2024 through 2034
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 200
Research and development expiration period	which expire in the years 2016 and 2017
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year	2035
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year	2016

COMMITMENTS AND CONTINGENCIES - Shedule Of Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Quarterly Financial Information [Line Items]
Net revenues	$ 2,679	$ 210	$ 341	$ 5,357	$ 529	$ 145	$ 35	$ 42	$ 8,587	$ 751
Operating expenses	3,389	2,615	2,739	3,845	2,984	2,791	3,307	3,868	12,588	12,950
Operating income (loss)	(710)	(2,405)	(2,398)	1,512	(2,455)	(2,646)	(3,272)	(3,826)	(4,001)	(12,199)
Net income (loss)	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (4,989)	$ (13,209)
Basic income (loss) per share (in dollars per share)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)
Diluted income (loss) per share (in dollars per share)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Jun. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Purdue Pharma [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Expense	$ 250,000		$ 500,000
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		150
Number of lawsuits served		50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint		445
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space		$ 25,000
Lease expiring date		March 31, 2017

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Direct Offering [Member]
Net offering costs	$ 603
Market Offering [Member]
Net offering costs	$ 8